Renal osteodystrophy is one of the major complications in patients with chronic renal failure, and has a considerable impact on mortality, as well as quality of life in these patients. Patients on dialysis reveal various degrees of hyperparathyroidism and bone mineralization, resulting in low, normal, or high bone turnover. To prevent the progression of renal osteodystrophy, tight control of secondary hyperparathyroidism, that is, normal bone turnover, is crucial. It has been suggested that normal bone turnover is achieved when blood levels of intact PTH are between 3 and 5 times the upper limit of normal (200-300 pg/ml) [1] . c94 However, adynamic bone disease, with low bone turnover revealed by bone histology, was reported in patients on dialysis with intact PTH levels of 10 times the upper limit of normal [1] Besides high bone turnover, adynamic bone disease is an emerging problem in patients on dialysis [2] that leads to a higher risk of hypercalcemia [3] and supposed risk of bone fracture [4, 5] . Indeed, the levels of intact PTH correlate poorly with the status of bone turnover [6, 7] Furthermore, there is no clear-cut evidence for a direct relationship between serum levels of active metabolites of vitamin D and bone turnover. To determine the dosage of vitamin D or its analogues, sensitive and accurate markers that refl ect bone turnover status are urgently needed to avoid low bone turnover and to achieve a better quality of life in hemodialysis patients.
Recently, Monier-Faugere et al. [8] reported that the PTH-(1-84)/large carboxy-terminal PTH fragments (C-PTH fragments) ratio predicted bone turnover with acceptable precision for biological measurements, and that a ratio 1 1 predicted high or normal bone turnover, while a ratio ! 1 indicated a low bone turnover. Blood levels of large C-PTH fragments were calculated by subtracting PTH-(1-84) from total PTH, and included several amino-terminally truncated fragments, of which PTH-(7-84) predominated. It has been reported that PTH-(7-84) acts as the most potent competitive antagonist among all tested PTH fragments, and that it regulates the expression or sensitivity of the PTH receptors [9] . The intact PTH assay recognizes PTH-(1-84) as well as amino-terminally truncated PTH fragments, i.e. PTH-(7-84), thus this assay recognizes both active and inactive PTH fragments.
Secondary hyperparathyroidism in chronic renal failure patients is due to vitamin D activating failure, accumulation of serum phosphorus, and a decrease of serum calcium. Active vitamin D and its analogues are now major therapeutic tools in uremic patients who have a defective activity of the renal 1 · -hydroxylase responsible for calcitriol synthesis. Thus, one would like to have a reliable marker for setting the dosage of vitamin D and its analogues. In light of these considerations, we hypothesized that the PTH-(1-84)/large C-PTH fragments ratio may refl ect the overall action of various PTH fragments, and could be a sensitive marker for vitamin D actions on PTH biosynthesis. In this investigation, we set a 2-week washout of vitamin D in chronic hemodialysis patients, re-started intravenous therapy of calcitriol or maxacalcitol, measured the PTH-(1-84)/large C-PTH fragments ratio during an 18-month period, and assessed its clinical signifi cance.
Methods

Patients
Seventeen patients with chronic renal failure on maintenance hemodialysis therapy at Teraoka Memorial Hospital were enrolled in this study during the years 2001-2003. Written informed consent was obtained from all patients , and this investigation was approved by the Ethical Committee at Teraoka Memorial Hospital. The inclusion criteria were intact PTH 1 300 pg/ml, and corrected calcium and phosphorus concentrations ! 10.5 and ! 6.5 mg/dl, respectively. All patients underwent hemodialysis 3 times a week with a total dialysis session of 12-15 h using a standard hemodialysis technique. The exclusion criteria were a history of parathyroidectomy, renal transplantation, or use of medications known to affect bone metabolism, such as glucocorticoids, diphenylhydantoin and cyclosporine. They did not suffer from diseases that may affect bone metabolism, such as malignancies, liver diseases, gastrointestinal diseases, tuberculosis, acquired immunodefi ciency syndrome, chronic alcoholism or drug addiction, or hemodialysisrelated amyloidosis.
Initially, 130 patients were screened and intact PTH levels in 17 patients (10 men and 7 women with a mean age of 57.1 8 8.5 and 64.7 8 13.7 years, respectively,) were 1 300 pg/ml. The mean duration on dialysis treatment was 141.1 8 68.9 months, and the causes of renal failure were chronic glomerulonephritis in 14 patients and diabetic nephropathy in 3 patients ( table 1 ). Fifteen out of 17 patients had been treated with either calcitriol or maxacalcitol, orally or intravenously.
Protocol
Treatment with vitamin D and its analogue was discontinued for at least 2 weeks to obtain baseline data. We then started administration of either calcitriol 0.5 Ì g i.v. or maxacalcitol 5 Ì g i.v. at the end of each hemodialysis session and continued for 78 weeks. During the study period, none of the patients received corticosteroids, or antiepileptics. We obtained blood samples before the dialysis session at the beginning of the study, and at 13, 26, 52 and 78 weeks, and measured bone-specifi c alkaline phosphatase (BAP), intact osteocalcin (iOC), tartrate-resistant acid phosphatase (Tr-ACP), PTH-(1-84), and the PTH-(1-84)/large C-PTH fragments ratio.
The monthly measurements of corrected calcium (calculated by [serum calcium (mg/dl) + 4 -serum albumin (g/dl)] when serum c95 albumin was ! 4), phosphorus, total alkaline phosphatase and intact PTH were performed. We adjusted the dosage of calcitriol or maxacalcitol to maintain the intact PTH levels between 150 and 250 pg/ml. During the investigation period, we administered calcitriol at dosages ranging from 0.5 to 1.5 Ì g per hemodialysis session, and maxacalcitol at 2.5-20 Ì g. If serum-corrected calcium levels were 1 11.5 mg/ml, we reduced the vitamin D dose. The nutritionists educated the patients with protein restriction diets 1-1.2 g protein/kg weight, and we also prescribed calcium-based phosphorus binders, such as calcium carbonate, when their serum phosphorus was 1 6.0 mg/dl, while Sevelamer hydrochroride or aluminum-based phosphorus binders were not used.
Biochemical and Hormonal Parameters
Serum calcium, phosphorus, albumin, and total alkaline phosphatase were measured by standard laboratory techniques. BAP was determined with an immunoassay with a monoclonal anti-bone alkaline phosphatase antibody coated on a microtiter plate (normal range 13.0-33.9 U/l for males, 9.6-35.4 U/l for females; Metra Biosystems, Mountain View, Calif., USA). Serum Tr-ACP was measured by UV methods (normal range 3.6-10.2 IU/l; Nitto Boseki Co. Ltd, Fukushima, Japan). Serum iOC was determined with the IRMA (immunoradiometric assay) method (normal range 3.1-12.7 ng/ml; Mitsubishi Chemistry Medical Bio Int., Tokyo, Japan). Serum intact PTH levels were determined with the IRMA technique based on double antibodies using polyclonal human antibodies generated against PTH-(39-84) immobilized onto plastic beads. A second polyclonal antibody was directed against PTH-(1-34) (Allegro intact PTH; normal range 10-65 pg/ml; Nichols Institute Diagnostics, San Juan Capistrano, Calif., USA). Total PTH was measured by polyclonal human antibodies generated against PTH-(39-84) immobilized onto plastic beads. A second polyclonal antibody is directed against PTH-(7-34) (total PTH; normal range 14-66 pg/ml; Scantibodies Laboratory Inc., Santee, Calif., USA). Plasma PTH-(1-84) was determined with the IRMA using a polyclonal antibody specifi c for PTH-(39-84). A second polyclonal antibody directed against PTH-(1-4) was used for the detection of PTH-(1-84) (whole PTH; normal range 7-36 pg/ml; Scantibodies Laboratory Inc.). Large C-PTH fragments were calculated by subtracting the PTH-(1-84) circulating levels from the total PTH, and the PTH-(1-84)/ large C-PTH fragments ratio was obtained.
Statistical Analyses
Results are expressed as mean 8 SD. An assigned signifi cance level of 0.01 was used. Repeated measures analysis of variance was used to compare calcitriol and maxacalcitol groups with respect to intact PTH, PTH-(1-84), and the PTH-(1-84)/large C-PTH fragments ratio. Comparisons of parameters between values at the baseline and values for chronological changes were done using Student's t test. Pearson's coeffi cients of correlation were obtained between large C-PTH fragments/total PTH ratios and corrected serum calcium. Computations and analyses were performed using StatView-J5.0.
Results
Clinical characteristics, serum biochemical and hormonal parameters at baseline and the end of study are listed in tables 1 and 2 , respectively. The corrected serum calcium levels increased signifi cantly at 78 weeks compared with baseline data (p ! 0.0001), while phosphorus levels did not change signifi cantly. Serum corrected calcium gradually increased during the study and statistical signifi cance was observed after 13 weeks. Phosphorus levels showed no marked fl uctuations, ranging from 5 to 6 mg/dl during the observation period ( fi g. 1 ). Meanwhile, serum corrected calcium increased to over 11.5 mg/dl with 17 events in 10 patients. However, serum corrected calcium was normalized immediately after reducing the dose of vitamin D.
All markers for bone turnover, ALP, BAP, iOC and Tr-ACP were higher than the upper limits of the reference range. However, they did not change signifi cantly during the observation period. Repeated measures of analysis of variance showed no differences between the calcitriol and maxacalcitol groups to with respect to intact PTH ( fi g. 2 A), PTH-(1-84), and the PTH-(1-84)/large C-PTH fragments ratio. In contrast, the average values of intact PTH and PTH-(1-84) levels decreased signifi cantly at 78 weeks compared with baseline (p ! 0.0001, p = 0.0008, respectively). The average values of both intact PTH and PTH-(1-84) levels decreased signifi cantly after 13 weeks, and these values remained lower than baseline data ( fi g. 2 B). Large C-PTH fragments signifi cantly decreased at 26 weeks, however they did not reveal signifi cant changes compared with baseline data at the end of the study ( fi g. 2 B). Average values of the PTH-(1-84)/total PTH ratio showed a continuous, statistically signifi cant decrease during the course of the study. The large C-PTH fragments/total PTH ratios revealed a mirror image pattern of these changes, and continuously increased ( fi g. 2 C).
The PTH-(1-84)/large C-PTH fragments ratios significantly decreased at 26 weeks, and further declined at the end of the intervention (p = 0.0004) ( fi g. 2 D). Accordingly, PTH-(1-84) was markedly suppressed compared with large C-PTH fragments after treatment with calcitriol or maxacalcitol, that is, the treatment with vitamin D and its analogue selectively inhibited the production of PTH-(1-84) from the parathyroid glands. Since a significant correlation has been reported between serum calcium and large C-PTH fragments/total PTH ratio, we investigated the correlation at baseline and at 78 weeks. There was no signifi cant correlation between the large C-PTH fragments/total PTH ratios and serum calcium levels at either baseline or at 78 weeks of this study ( fi g. 3 A). Moreover, there was no signifi cant correlation between the change of large C-PTH fragments/total PTH ratio and the change of serum calcium levels (p = 0.1366) ( fi g. 3 B). There was no signifi cant correlation between PTH-(1-84)/large C-PTH fragments ratios and serum calcium levels at baseline; however, the PTH-(1-84)/large C-PTH fragments ratio showed a weak correlation with serum calcium levels at 78 weeks ( fi g. 4 A). There was no significant correlation between the change of the PTH-(1-84)/ large C-PTH fragments ratio and the change of serum calcium levels (p = 0.7315), thus ruling out the possibility that increased calcium due to vitamin D therapy tightly is linked to a decrease in the PTH-(1-84)/large C-PTH fragments ratio ( fi g. 4 B).
Discussion
Intact PTH levels ! 65 pg/ml are generally predictive of low bone turnover, while levels 1 500 pg/ml generally indicate normal or high turnover. However, intact PTH levels of most dialysis patients distribute between 65 and 450 pg/ml [10] [11] [12] . In clinical practice, we administer the active form of vitamin D and adjust the dosages to maintain intact PTH levels between 200 and 300 pg/ml to achieve normal bone turnover [6] . However, intact PTH levels 1 500 pg/ml have been found in some dialysis patients with low turnover, while intact PTH levels as low as 100 pg/ml have been found in patients with bone turnover above normal. It has been demonstrated that large C-PTH fragments that accumulate in the serum of uremic patients can interfere with the measurement of intact PTH by methods currently in use [13] .
PTH is synthesized as a larger precursor, pre-pro-PTH, and a 25-residue pre-sequence, i.e. signal sequence, is cleaved off during transit across the membrane of the Fig. 1 . Corrected serum calcium and phosphorus levels. Serum calcium corrected by albumin levels increased signifi cantly at 13 weeks and further increased during the study period. Phosphorus levels showed no marked fl uctuations within the range of 5-6 mg/dl during the observation period (* p ! 0.01, ** p ! 0.001, *** p ! 0.0001). c97 endoplasmic reticulum. Pro-PTH is then transported to the trans -Golgi network, where the short 6-residue prosequence is cleaved, and the mature PTH-(1-84) is packaged into secretory vesicles and granules. Furin has a neutral pH optimum, and functions in the trans -Golgi network in the process of conversion of pro-PTH to PTH. Similarly, proprotein convertase 7 (PC7) can appropriately cleave pro-PTH in parathyroid gland cells having a regulated secretory pathway [14] . In addition to these proteases, the co-localization of various proteases and PTH Fig. 2 . Intact PTH, PTH-(1-84) and large C-PTH fragment levels. There was no statistical difference in intact PTH levels between the maxacalcitol and calcitriol groups during the observation period ( A ). The average values of both intact PTH and PTH-(1-84) decreased signifi cantly after 13 weeks, and these values remained lower than baseline data. Large C-PTH fragments signifi cantly decreased at 26 weeks, however they did not reveal signifi cant changes compared with baseline data at the end of the study ( B ). Average values of the PTH-(1-84)/total PTH ratio showed a continuous, statistically signifi cant decrease, while the large C-PTH fragments/total PTH ratio increased during the course of study ( C ). PTH-(1-84)/large C-PTH fragments ratios signifi cantly decreased at 26 weeks, and declined further at the end of the intervention (p = 0.0004) ( D ) (* p ! 0.01; ** p ! 0.001; *** p ! 0.0001). c98 in secretory granules explains the observation that a portion of the PTH secreted from parathyroid glands consists of large C-PTH fragments. Intracellular proteolysis of mature bioactive PTH has been reported and it is responsible for the regulation of the amount of hormone available for secretion in response to changes in serum calcium, which is known to be mediated by calpains and cathepsin B and D [15, 16] Recently, proteosome inhibitors have been shown to cause the accumulation of prepro-PTH and pro-PTH and decreased secretion of mature PTH. [17] Accordingly, there are several steps which infl uence the biogenesis, processing and secretion of PTH in parathyroid glands.
Levels of large C-PTH fragments in uremic patients are greater than in healthy subjects because of increased parathyroid gland secretion or a lower rate of disposal and longer half-life of these molecules in uremia. Therefore, the 1-84 to large C-PTH fragments ratio is markedly higher in healthy subjects than in those with chronic renal failure [18] . Large C-PTH fragments, mainly consisting of PTH-(7-84), are biologically inactive, and have antagonistic effects on PTH-(1-84) [1] . Specifi cally, PTH-(7-84) decreases bone resorption, bone turnover, and serum calcium, does not stimulate adenylate cyclase, and appears to operate through a C-terminal PTH receptor, while PTH-(1-84) operates through a type 1 PTH receptor [19] . Fig. 3 . Relationship between corrected serum calcium and large C-PTH fragments/total PTH ratio. There was no correlation between the large C-PTH fragments/total PTH ratio and serum calcium level at either baseline or at 78 weeks ( A ). Moreover, there was no signifi cant correlation between changes of large C-PTH fragments/total PTH ratio and serum calcium ( B ).
Fig. 4.
Relationship between corrected serum calcium and PTH-(1-84)/large C-PTH fragments ratio. There was a signifi cant correlation between the PTH-(1-84)/large C-PTH fragments ratio and serum calcium levels at 78 weeks (p = 0.0099) ( A ). However, there was no signifi cant correlation between changes of the PTH-(1-84)/ large C-PTH fragments ratio and serum calcium ( B ).
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As reported in previous investigations [20] , the longterm administration of the active form of vitamin D suppresses secretion of both PTH-(1-84) and large C-PTH fragments. Although the active form of vitamin D has no direct effect on PTH secretion, it dramatically suppresses PTH gene transcription. In addition to decreased release of PTH from the parathyroid glands, the administration of the active form of vitamin D alters the biosynthesis and intracellular fragmentation of PTH. As described in the current study, the PTH-(1-84)/large C-PTH fragments ratio signifi cantly decreased during 18 months of vitamin D therapy. Neither calcium nor the active form of vitamin D infl uenced furin or PC7 mRNA levels, which are involved in pro-PTH to PTH conversion. One can thus speculate that other, yet unidentifi ed proteases in secretory granules may be up-regulated by vitamin D administration and produce PTH-(7-84).
Calcium also regulates the biosynthesis of PTH. In vivo studies show that acute hypocalcemia in rats leads to an increase in PTH mRNA within an hour. In contrast, hypercalcemia leads to little or no change in PTH mRNA. Coen et al. [18] reported a signifi cant positive correlation between large C-PTH fragments/total PTH ratios and serum calcium levels. Small increments in serum calcium levels are able to enhance the relative secretion of C-terminal fragments. However, in the current study, we did not fi nd a correlation between changes in calcium and the large C-PTH fragments/total PTH ratio. We thus concluded that the infl uence of calcium on the large C-PTH fragments/total PTH ratio was minimal, and that the administration of the active form of vitamin D mainly altered the ratio.
The decreased PTH-(1-84)/large C-PTH fragments ratio suggested that overall biological actions of PTH in hemodialysis patients may be overestimated by the intact PTH assay, which recognizes both PTH-(1-84) and large C-PTH fragments. The parathyroid gland controls bone metabolism by secreting two hormones with opposing biological activities. The ultimate goal of secondary hyperparathyroidism therapy is to suppress the level of PTH to the target range where there is hypercalcemia, high turnover bone diseases, or adymanic low bone turnover disease from oversuppression. As reported earlier, a PTH-(1-84)/large C-PTH fragments ratio ! 1 indicates a low bone turnover revealed by histological analyses of bone biopsy specimens using tetracycline labeling [8] . In our hemodialysis patients, after 18 months of vitamin D treatment, almost all patients achieved intact PTH levels 1 150 pg/ml; however, 6 patients revealed lower PTH-(1-84)/large C-PTH fragments ratios, i.e. ! 1. Whether or not the PTH-(1-84)/large C-PTH fragments ratio exactly correlates with bone turnover and the data in hemodialysis patients is still controversial. In future studies, we would investigate whether the PTH-(1-84)/large C-PTH fragments ratio refl ects bone turnover evaluated by bone biopsy. The therapeutic target range of the PTH-(1-84)/ large C-PTH fragments ratio also needs to be defi ned.
In conclusion, we raised the possibility that the PTH-(1-84)/large C-PTH fragments ratio may be a benefi cial marker for the evaluation of overall biological activity of PTH action in chronic dialysis patients treated with the active form of vitamin D and its analogues. The administration of the active form of vitamin D signifi cantly reduced the PTH-(1-84)/large C-PTH fragments ratio and altered the process of intracellular metabolism and secretion of PTH. Certainly, the relation between bone histological fi ndings before and after treatment with vitamin D, as well as the PTH-(1-84)/large C-PTH fragments ratio need to be extensively investigated in future clinical studies.
